Study of High Sensitive-CRP and Cardiac Marker Enzymes in Acute Coronary Syndrome

• Main Authors: Srikrishna R, Ramesh S. T, Girishbabu R. J
• Format: Article
• Language: English
• Published: Krishna Institute of Medical Sciences University 2015-04-01
• Series: Journal of Krishna Institute of Medical Sciences University
• Subjects: C-reactive protein; acute myocardial infarction; acute coronary syndrome; inflammation.
• Online Access: http://jkimsu.com/jkimsu-vol4no2/JKIMSU,Vol.4,No.2,April-June2015Page107-113.pdf
• ISSN: 2231-4261; 2231-4261

Background: Inflammation has been proposed as a contributor to different stages in the pathogenesis of Coronary Heart Disease (CHD). High sensitive C-Reactive Protein (hs-CRP), an acute-phase plasma protein synthesized by the liver, is the most extensively studied systemic marker of inflammation. Elevated hsCRP concentrations early in Acute Coronary Syndrome (ACS), prior to the tissue necrosis, may be a surrogate marker for cardiovascular co-morbidities. The cardiac marker enzymes Creatine Kinase myocardial bound (CK-MB), Aspartate Aminotransferase (AST) and lactate dehydrogenase (LDH) have been known to be increased in coronary artery diseases. Objective: The aim of the study was to measure hs-CRP levels and other cardiac marker enzymes in ACS patients and to compare the levels of hs-CRP with other cardiac marker enzymes between ST Elevation Myocardial Infarction (STEMI) and Non-ST Elevation Myocardial Infarction (NSTEMI) patients. Material and Methods: The study group consisted of 207 consecutive patients admitted to Sri Siddhartha Medical College Hospital within the first 6 hours from the onset of chest pain. Patients were diagnosed as Unstable Angina (UA), (n=84); STEMI (n=63) and NSTEMI (n=60). ACS patients were compared with 211 healthy age and sex matched controls. Hs-CRP, CK-MB, AST and LDH levels were measured by standard methods in both groups at baseline and forcases at 36-48 hours i.e. Peak levels. Results: ACS patients had significantly (p<0.05) higher levels of hs-CRP, CKMB, AST and LDH in comparison to controls at baseline. Hs-CRP, CK-MB, AST and LDH levels were significantly higher in STEMI patients compared to NSTEMI patients (p<0.05) at baseline. There was a significant difference regarding peak hs-CRP levels between the two groups, as STEMI patients had significantly higher peak hs-CRP levels compared to NSTEMI patients (p<0.05). Conclusion: STEMI patients have significantly higher peak hsCRP levels compared to NSTEMI patients. These data suggest that inflammatory processes play an independent role in the pathogenesis of myocardial infarction. Thus, Hs-CRP assessment may assist in risk stratification after myocardial infarction.